China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2012 (Full Text)
I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord Medicines Corporation Ltd.
(hereinafter referred to as the Company) and its directors, supervisors and senior executives hereby confirm that
there are no any fictitious statements, misleading statements, or important omissions carried in this report, and
shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole
contents.
The Third Quarterly Financial Report of 2012 has not been audited by CPAs.
All directors of the Company are attended the communication voting Meeting.
Chairman of the Board Mr. Wei Yulin, Director GM Mr. Yan Zhigang, CFO Mr. Wei Pingxiao and Financial
Manager Mr. Chi Guoguang hereby confirm that the Financial Report of the Third Quarterly Report is true and
complete.
II. Company Profile
(I) Major accounting data and financial indexes
Whether retroactive adjusted on previous financial report or not
√ Yes □No □Not applicable
Increase/decrease in this
period-end over
2011.12.31
2012.9.30 period-end of last year
(%)
Before adjustment After adjustment After adjustment
Total assets (RMB) 9,050,106,887.81 7,665,759,761.04 7,680,576,330.72 17.83%
Owners’ equities attributable
to the shareholders of listed 1,656,701,257.46 1,350,217,871.35 1,350,093,276.86 22.71%
company (RMB)
Share capital (Share) 288,149,400.00 288,149,400 288,149,400.00 0%
Net assets per share
attributable to the
5.749 4.686 4.685 22.71%
shareholders of listed
company (RMB/Share)
Increase/decrease over Increase/decrease over
January- September of
July- September of 2012 the same period of the the same period of the
2012
last year (%) last year (%)
Total operating income
4,693,270,824.15 19.45% 13,496,523,170.35 21.17%
(RMB)
Net profit attributable to the
shareholders of listed 117,041,639.67 44.64% 357,075,630.31 45.29%
company (RMB)
Net cash flow arising from
-- -- 12,085,264.80 106.38%
operating activities (RMB)
Net cash flow arising from
operating activities per share -- -- 0.042 106.38%
(RMB/Share)
Basic earnings per share
0.406 44.64% 1.239 45.29%
(RMB/Share)
Diluted earnings per share
0.406 44.64% 1.239 45.29%
(RMB/Share)
Weighted average return on
7.28% 0.68% 23.73% 2.51%
equity (%)
1
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Weighted average return on
equity after deducting
6.87% 0.54% 23.83% 4.00%
non-recurring gains and losses
(%)
Note: (1) Basic EPS and diluted EPS should be listed base on the data attributable to shareholders of listed company;
(2) For the retroactive adjustment on financial data in last period, listed the data after and before adjustment respectively in aspect of
period-end of last year and same period of last year.
Items and amount with non-recurring gains/losses deducted
√Applicable □ Not applicable
Amount from
Item year-begin to Note
period-end (RMB)
Mainly due to the property disposal losses
RMB 8.83 million from urban renewal
Gains and losses from disposal of non-current assets -8,763,718.90
relocation in Guangxi Sinopharm Logistic,
subsidiary of the Company
Tax refund or exemption out of authorization, with absence
of official approval document or accidentally
Mainly including: relocation compensation
Governmental subsidy calculated into current gains and
for urban redevelopment RMB 13.26 million,
losses(while closely related with the normal business of the
technology reforming subsidy and rewards
Company, excluding the fixed-amount or fixed-proportion 25,054,139.19
for hi-tech enterprise RMB 7.71 million and
governmental subsidy according to the unified national
financial discount compensation RMB 3
standard)
million
Fund occupation expenses received from non-financial
enterprises that reckon into current gains/losses
Income occurred when investment cost paid by enterprise
for obtaining subsidiaries, associates and joint ventures are
lower than its share in fair value of net realizable assets of
invested units
Gains and losses from exchange of non-monetary assets
Gains and losses from entrusted investment or management
assets
Various asset impairment reserve provided for force
majeure, such as natural disaster
Gains/losses from debt reorganization
Reorganization expenses, such as expenditure for allocation
of employees and integration fee
Gains and losses from excess of transaction which are
conducted on a non-fair-valued basis over its fair value
Net profit of Sinopharm Wuzhou, which
Current net gains and losses of subsidiaries occurred from
acquires under same control, from
combination under the same control commencing from -240,695.14
period-begin to consolidation date (January –
period-begin to combination date
February)
Gains and losses from contingent events which has no
relation with normal business of the Company
Gains and losses from change of fair values of
held-for-transaction financial assets and financial liabilities
except for the effective hedge business related to normal
business of the Company, and investment income from
disposal of transactional financial assets and liabilities and
financial assets available for sale
Reversal of impairment reserve for account receivable with
1,437,760.48
separate impairment testing
gains/ losses from external entrustment loans
Gains and losses arising from change of fair value of
investment properties whose follow-up measurement are at
fair value
Affect upon current gains/losses arising from the one-off
adjustment in subject to requirement of laws and rules in
2
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
relation to taxation and accounting
Income from entrusted custody operation
Mainly refers to the compensation RMB 17.6
million paid for termination of Che Bei
project from subsidiary Guangdong Huixin
Other non-operating income and expenditure except the
-19,718,077.99 and vary relocation expenses RMB 2.93
abovementioned
million arising from subsidiary Guangxi
Sinopharm Logistic, which resulted by the
urban redevelopment
Other item that satisfied the definition of non-recurring
gains and losses
Influenced amount of minority shareholders’ equity -834,180.67
Impact on income tax 1,437,169.78
Total -1,627,603.25 --
Note: non-recurring gains/losses are listed before taxation
Explanation on ―Other item that satisfied the definition of non-recurring gains and losses‖ and defined
non-recurring gains and losses as recurring gain/loss according to natures and characteristic of self-operation
status
Item Amount involved (RMB) Note
(II) Total shareholders at period-end and top ten shareholders
Total number of shareholders
12,305
at the end of report period
Particulars about the shares held by the top ten shareholders with unrestricted conditions
Amount of Type/amount of shares
Shareholders unrestricted shares
held at period-end Type Amount
SINOPHARM GROUP CO., LTD. 110,459,748 RMB common share 110,459,748
ABC—Jinshun Greatwall Domestic
7,354,323 RMB common share 7,354,323
Demand Growth II Stock Fund
ICBC － GUANGFA JUFENG STOCK
7,224,699 RMB common share 7,224,699
FUND
HTHK/CMG FSGUFP-CMG FIRST Domestically listed foreign
7,032,720 7,032,720
STATE CHINA GROWTH FD share
ABC － GREATWALL ANXIN RETURN
5,940,382 RMB common share 5,940,382
MIXED FUND
ICBC—Harvest Theme New Power Stock
5,442,238 RMB common share 5,442,238
Fund
Finance New Blue-Chip Securities
5,002,143 RMB common share 5,002,143
Investment Fund
CCB—Greatwall consumer growth stock
4,840,817 RMB common share 4,840,817
fund
Domestically listed foreign
VALUE PARTNERS CLASSIC FUND 4,728,704 4,728,704
share
ICBC—UBS SDIC Core Enterprise Stock
4,366,971 RMB common share 4,366,971
Fund
The fund manager of ABC－Greatwall Anxin Return Mixed Fund and CCB-Greatwall
Explanation on shareholders consumer growth stock fund all refers to the Greatwall Fund Management Co., Ltd.; it
is unknown that there exists no associated relationship or belongs to the consistent
3
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
actionist among the other tradable shareholders regulated by the Management Measure
of Information Disclosure on Change of Shareholding for Listed Companies.
III. Significant events
(I) Particulars about material changes in items of main accounting statement and financial
index, and explanations of reasons
√Applicable □Not applicable
1. Monetary fund: decrease RMB 290.55 million over that of period-begin with growth rate of -30.49%. Main reasons are the
increase of operational payment, equity paid for new company purchased and short-term loans paid.
2. Account receivable: increase RMB 1096.34 million over that of period-begin with growth rate of 30.62% mainly due to the
soaring balance of account receivable stimulated by raising sales.
3. Other account receivable: increase RMB 19.44 million over that of period-begin with growth rate of 67.82%, which mainly
affected by the new purchased company as well as the increase of reserve fund and other vary business-running amount.
4. Other current assets: decrease RMB 2.9 million over that of period-begin with growth rate of -37.93%, mainly because the retained
payable VAT and enterprise income taxes decreased.
5. Construction in progress: decrease RMB 43.55 million over that of period-begin with growth rate of -33.23%, mainly because the
project of logistic center and sterile workshop, newly established by subsidiary of the Company Sinopharm Guangxi and Suzhou
Wanqing respectively, are transfer to fixed assets for part of the project completed.
6. Goodwill: increase RMB 36.32 million over that of period-begin in balance with growth rate of 67.82%, mainly affected by the
newly purchasing of Sinopharm Zhao Qing, Sinopharm Jiang Men and Sinopharm Shao Guang, the enterprise under difference
control.
7. Other non-current assets: increase RMB 127.56 million over that of period-begin in balance with growth rate of 316.74%, mainly
because the in-kind compensation obtained by subsidiary Guangxi Logistic for the relocation due to urban reconstruction
implemented by the Government; meanwhile, the equipment purchasing amount paid in advance from subsidiary Zhijun
Pharmaceutical increased.
8. Account payable: increase RMB 885.06 million over that of period-begin with growth rate of 35.45%, mainly because the
purchasing stimulated by the soaring sales which makes the growth of payable in balance correspondingly.
9. Account received in advance: decrease RMB 20.89 million over that of period-begin with growth rate of -35.58%, mainly because
the account received in advance, which qualify the income recognization, have been transfer to sales income at period-begin.
10. Non-current liability due within one year: increase RMB 43.21 million over that of period-begin in balance with growth rate of
180.35%, mainly because the long-term loans due within one year increased and the promotional credit for products due within one
year increased in subsidiary Zhijun Pharmaceutical.
11. Other non-current liability: increase RMB 118.57 million over that of period-begin in balance with growth rate of 125.81%,
mainly because the compensation obtained by subsidiary Guangxi Logistic for the relocation due to urban reconstruction
implemented by the Government.
12. Capital reserve: decrease RMB 3.19 million over that of period-begin in balance with growth rate of -36.46%, mainly due to the
adjustment in year-begin for purchasing of Sinopharm Wuzhou, under the same control, the retroactive adjusted capital reserve
decreased after combination in this period.
13. Business tax and surcharge: gains a y-o-y growth of RMB 10.58 million with growth rate of 41.22%, mainly because the increase
of business income and the higher individual tax-burden ratio in Shenzhen area such as city construction tax.
14. Losses of impairment of assets: gains a y-o-y growth of RMB 9.85 million with growth rate of 144.43%, mainly because the
accrual provision for obsolete stock increased.
15. Business profit: gains a y-o-y growth of RMB 161.54million with growth rate of 52.98%; total profit gains a y-o-y growth of
RMB 138.9 million with growth rate of 42.86%; net profit gains a y-o-y growth of RMB 116.32 million with growth rate of 46.87%;
net profit attributable to owners of parent company gains a y-o-y growth of RMB 111.32 million with growth rate of 45.29 % and
basic EPS gains a y-o-y growth of RMB 0.386/Share with growth rate of 45.29%. Mainly because the growth of sales income and
profitability
16. Non-operating income: gains a y-o-y growth of RMB 7.57 million with growth rate of 38.82%, mainly because the increase of
income from disposal of fixed assets and vary government grand obtained increased.
17. Non-operating expenditure: gains a y-o-y growth of RMB 30.21 million with growth rate of 10,417.24%, mainly because
compensation paid for termination of Che Bei project from subsidiary Guangdong Huixin and vary relocation expenses and losses
arising from subsidiary Guangxi Logistic, which resulted by the urban redevelopment.
18. Taxes refunds: gains a y-o-y growth of RMB 0.61 million with growth rate of 58.59%, mainly because the y-o-y growth in aspect
of income tax and export tax rebate received in this period.
19. Taxes paid: gains a y-o-y growth of RMB 105.48 million with growth rate of 39.64%, mainly because the increase of business
income and the higher individual tax-burden ratio.
20. Net cash flow arising from operating activities: gains a y-o-y growth of RMB 201.43 million with growth rate of 106.39%,
mainly because the increase of operating income, meanwhile, reinforce in aspect of management of receivables, more cash flow
obtained for better matches in paid-received.
21. Cash received from investment: received a y-o-y decrease of RMB 1.83 million with growth rate of -100%, mainly because there
has the gains/losses obtained from original shareholders of Chinese Medicine Company, settlement from assessment base date to the
completion day of equity transfer, at same period of last, and no such business occurred in this period.
22. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: gains a y-o-y growth of RMB 50.02
million with growth rate of 1232.02%, mainly because the compensation obtained from Guangxi Sinopharm Logistic for relocation
due to urban redevelopment in this period.
4
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
23. Other cash received with investment activities concerned: received a y-o-y decrease of RMB 0.65 million with growth rate of
-100%, mainly because the economic compensation for office-leaving and retirement paid by original shareholders have been
received in September 2011 by subsidiary Sinopharm Wuzhou, and no such business in this period.
24. Net cash paid from subsidiary and other operation units: gains a y-o-y growth of RMB 49.73 million with growth rate of 869.41%,
mainly because the newly purchased company in this period.
25. Other cash paid with investment activities concerned: received a y-o-y decrease of RMB 9.78 million with growth rate of -100%,
mainly because at same period of last year, subsidiary of the Company Sinopharm Nanjing paid the tail-payment for acquisition of
Nanning Medicine Company, and no such business in this period.
26. Cash received from bond issuance: gains a y-o-y growth of RMB 398.4 million with growth rate of 100%, mainly because
short-term financing bonds are offering in this period, and no such business occurred in last period.
27. Other cash received with financing activities concerned: received a y-o-y decrease of RMB 391.28 million with growth rate of
-60.77%, mainly because the factoring for entrust loans and account receivable from Sinopharm decreased in this period.
28. Cash paid for debt settlement: gains a y-o-y growth of RMB 460 million with growth rate of 100.33%, mainly because of the
more loans and soaring debts paid.
29. Cash paid for distribution of dividend, profit or interest: gains a y-o-y growth of RMB 53.82 million with growth rate of 54.11%,
mainly because the payable interest growth stimulated by the enlargement of financing, meanwhile the cash dividend increased.
30. Dividend, profit paid to minority shareholders by subsidiary: received a y-o-y decrease of RMB 0.57 million with growth rate of
-38.26%, mainly because the profit paid to minority shareholders from subsidiary Yanfeng decreased in this period.
(II) Progress of significant events, their influences, and analysis and explanation of their
solutions
1. Qualified opinion
□Applicable √Not applicable
2. Particular about fund offers to controlling shareholders or associated parties and external
guarantee that against the regulation.
□Applicable √ Not applicable
3. Particular about signing and implementation on significant contracts of ordinary
management.
□Applicable √ Not applicable
4. Other
√ Applicable □Not applicable
1. The Company entered into the Financial Service Agreement and Credit Line Agreement with Sinopharm Group Financial Co., Ltd
respectively on 12 September 2012 and 18 September 2012, and applying loans from Financial Company since the date signing.
Ended as 30 September 2012, the deposit balance of the Company, loans balance, guarantee amount and note discount occurring in
Financial Company are RMB 0.9938 million, RMB 60 million, RMB 0 and RMB 9.9505 million respectively. More details of risk
assessment for Sinopharm Group Financial Co., Ltd, please found in Sustainability Risk Assessment on Sinopharm Group Financial
Co., Ltd from China National Accord Medicines Corporation Ltd. disclosed on the same day.
2. The Company purchased 70% shares of Sinopharm Shaoguan Co., Ltd on 18 July 2012 with transaction price of RMB 13.58
million. Pricing principle for this assets purchasing are based on the value assessment of book value of balance sheet dated 31
December 2011, property with assets concerned as well as liability and credit are completed their ownership transfer in this period.
Net profit RMB 414,300 contributed to the Company from the day of purchasing to end of this report period.
3. A new wholly-owned subsidiary Sinopharm Zhongshan Co., Ltd established in September 2012 with register capital of RMB 10
million; net profit RMB 0 contributed to the Company from day of established to end of this report period.
(III) Commitments made by the Company or shareholders holding above 5% shares of the
Company in reporting period or extending to reporting period.
□Applicable √ Not applicable
(IV) Estimation of operation performance for year of 2012
□Applicable √ Not applicable
5
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
(V) Particulars about other significant events which needed explanations
1. Particular about security investment
□Applicable √Not applicable
2. Particulars about derivatives investment
□Applicable √Not applicable
3. Particulars about the positions of derivatives investment at the end of report period
□Applicable √Not applicable
4. Registration form of receiving research, communication and interview in the report period
□Applicable √Not applicable
5. Corporate bond issuance
Whether corporate bond issued or not
□ Yes √ No
IV. Appendix
(I) Financial statement
Whether consolidated statement or not:
√ Yes □ No □Not applicable
Unless otherwise, currency for this statement refers to CNY (RMB)
1. Consolidated Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Items Balance at period-end Balance at period-begin
Current assets:
Monetary funds 662,400,497.30 952,950,167.56
Settlement provisions
Capital lent
Transaction finance asset
Notes receivable 650,807,753.66 534,922,741.30
Accounts receivable 4,676,845,861.96 3,580,506,395.70
Accounts paid in advance 82,236,734.62 65,857,961.31
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable
Dividend receivable
Other receivables 48,091,838.81 28,656,020.58
Purchase restituted finance asset
6
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Inventories 1,543,708,602.09 1,313,213,414.68
Non-current asset due within one
year
Other current assets 4,750,684.89 7,653,736.21
Total current assets 7,668,841,973.33 6,483,760,437.34
Non-current assets:
Granted loans and advances
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 107,299,255.95 95,799,627.42
Investment real estate 84,055,422.76 86,164,929.70
Fixed assets 639,190,456.33 602,205,927.87
Construction in progress 87,491,369.59 131,042,772.59
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 136,499,274.35 119,601,478.86
Expense on Research and
4,538,187.71 3,998,433.69
Development
Goodwill 89,878,833.14 53,555,677.09
Long-term expenses to be
17,992,430.83 20,103,138.99
apportioned
Deferred income tax asset 46,484,331.07 44,070,064.25
Other non-current asset 167,835,352.75 40,273,842.92
Total non-current asset 1,381,264,914.48 1,196,815,893.38
Total assets 9,050,106,887.81 7,680,576,330.72
Current liabilities:
Short-term loans 1,948,849,031.51 1,839,838,065.68
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Transaction financial liabilities
Notes payable 981,377,595.67 1,059,426,952.84
Accounts payable 3,381,811,187.30 2,496,755,405.30
Accounts received in advance 37,820,246.44 58,705,230.49
Selling financial asset of repurchase
Commission charge and commission
payable
Wage payable 149,032,664.34 142,414,446.06
7
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Taxes payable 68,795,140.40 63,600,830.11
Interest payable 8,081,511.95 10,451,229.03
Dividend payable
Other accounts payable 376,020,313.50 346,965,182.34
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Non-current liabilities due within 1
67,173,000.00 23,960,000.00
year
Other current liabilities
Total current liabilities 7,018,960,691.11 6,042,117,341.85
Non-current liabilities:
Long-term loans 71,270,657.51 93,082,967.96
Bonds payable
Long-term account payable 32,259.60 35,536.20
Special accounts payable 4,287,000.00 4,519,000.00
Projected liabilities
Deferred income tax liabilities 22,772,603.90 19,900,787.30
Other non-current liabilities 212,810,029.77 94,245,023.54
Total non-current liabilities 311,172,550.78 211,783,315.00
Total liabilities 7,330,133,241.89 6,253,900,656.85
Owner’s equity (or shareholders’
equity):
Paid-up capital (or share capital) 288,149,400.00 288,149,400.00
Capital public reserve 5,550,338.57 8,735,305.04
Less: Inventory shares
Reasonable reserve
Surplus public reserve 63,480,745.16 63,480,745.16
Provision of general risk
Retained profit 1,299,520,773.73 989,727,826.66
Balance difference of foreign
currency translation
Total owner’s equity attributable to
1,656,701,257.46 1,350,093,276.86
parent company
Minority interests 63,272,388.46 76,582,397.01
Total owner’s equity(or
1,719,973,645.92 1,426,675,673.87
shareholders’ equity)
Total liabilities and owner’s
9,050,106,887.81 7,680,576,330.72
equity(or shareholders’ equity)
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
8
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
2. Balance Sheet of parent company
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 62,142,166.37 164,840,499.86
Transaction finance asset
Notes receivable 4,003,841.66 8,718,971.96
Accounts receivable 387,599,346.37 295,227,856.20
Accounts paid in advance 3,904,097.93 3,148,580.55
Interest receivable
Dividend receivable
Other receivables 751,577,280.60 704,287,016.32
Inventories 112,921,115.92 125,157,825.01
Non-current asset due within one
year
Other current assets 39,482.38 39,482.38
Total current assets 1,322,187,331.23 1,301,420,232.28
Non-current assets:
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 1,455,328,750.33 1,332,527,041.51
Investment real estate 7,709,682.50 8,841,071.50
Fixed assets 29,188,512.41 32,866,561.06
Construction in progress 545,247.24 253,886.24
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 26,583,847.74 27,426,551.44
Expense on Research and
Development
Goodwill
Long-term expenses to be
8,176,392.32 9,030,726.77
apportioned
Deferred income tax asset 3,037,448.27 5,335,693.52
Other non-current asset 7,000,000.00 7,000,000.00
Total non-current asset 1,537,569,880.81 1,423,281,532.04
Total assets 2,859,757,212.04 2,724,701,764.32
Current liabilities:
Short-term loans 718,586,305.93 417,648,980.60
9
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Transaction financial liabilities
Notes payable 117,668,217.97 120,293,155.72
Accounts payable 329,857,440.73 343,946,734.72
Accounts received in advance 811,020.56 249,535.25
Wage payable 42,881,480.49 24,966,511.90
Taxes payable 2,109,762.60 1,640,177.39
Interest payable 2,701,712.74 868,585.17
Dividend payable
Other accounts payable 409,012,653.17 865,237,491.48
Non-current liabilities due within 1
year
Other current liabilities
Total current liabilities 1,623,628,594.19 1,774,851,172.23
Non-current liabilities:
Long-term loans
Bonds payable
Long-term account payable
Special accounts payable 800,000.00 1,032,000.00
Projected liabilities
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities
Total non-current liabilities 4,573,319.00 4,805,319.00
Total liabilities 1,628,201,913.19 1,779,656,491.23
Owner’s equity (or shareholders’
equity):
Paid-up capital (or share capital) 288,149,400.00 288,149,400.00
Capital public reserve 14,348,726.93 14,116,726.93
Less: Inventory shares
Reasonable reserve
Surplus public reserve 63,480,745.16 63,480,745.16
General risk reserve
Retained profit 865,576,426.76 579,298,401.00
Balance difference of foreign
currency translation
Total owner’s equity(or
1,231,555,298.85 945,045,273.09
shareholders’ equity)
Total liabilities and owner’s
2,859,757,212.04 2,724,701,764.32
equity(or shareholders’ equity)
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
10
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
3. Consolidated Profit Statement (this report period)
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Item Amount in this period Amount in last period
I. Total operating income 4,693,270,824.15 3,929,202,842.44
Including: Operating income 4,693,270,824.15 3,929,202,842.44
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 4,553,798,457.73 3,835,382,657.88
Including: Operating cost 4,287,493,976.95 3,608,714,685.80
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 9,602,518.29 10,045,621.45
Sales expenses 110,788,641.71 90,646,064.21
Administration expenses 102,852,218.88 90,809,745.21
Financial expenses 34,776,427.52 34,226,609.67
Losses of devaluation of asset 8,284,674.38 939,931.54
Add: Changing income of fair
value(Loss is listed with ―-‖)
Investment income (Loss is listed
9,003,930.24 8,459,883.59
with ―-‖)
Including: Investment income on
9,003,930.24 8,459,883.59
affiliated company and joint venture
Exchange income (Loss is listed
with ―-‖)
III. Operating profit (Loss is listed
148,476,296.66 102,280,068.15
with ―-‖)
Add: Non-operating income 7,963,730.94 4,481,813.60
Less: Non-operating expense 586,303.05 77,727.87
Including: Disposal loss of
41,703.16 39,743.32
non-current asset
IV. Total Profit (Loss is listed with
155,853,724.55 106,684,153.88
―-‖)
Less: Income tax expense 34,568,724.21 25,930,899.43
11
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
V. Net profit (Net loss is listed with
121,285,000.34 80,753,254.45
―-‖)
Including: net profit realized
before consolidation by mergered 0.00 -183,525.97
party
Net profit attributable to owner’s of
117,041,639.67 80,918,614.66
parent company
Minority shareholders’ gains and
4,243,360.67 -165,360.21
losses
VI. Earnings per share -- --
i. Basic earnings per share 0.406 0.281
ii. Diluted earnings per share 0.406 0.281
VII. Other consolidated income
VIII. Total comprehensive income 121,285,000.34 80,753,254.45
Total consolidated income
attributable to owners of parent 117,041,639.67 80,918,614.66
company
Total consolidated income
4,243,360.67 -165,360.21
attributable to minority shareholders
The merger realized net profit RMB 0.00 before consolidation during enterprises consolidation under a same
control.
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
4. Profit Statement of parent company (this report period)
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Items Amount in this period Amount in last period
I. Operating income 549,406,861.76 520,183,508.48
Less: operating cost 524,292,949.74 493,296,835.21
Operating tax and extras 1,454,213.60 1,167,722.05
Sales expenses 10,533,270.73 10,542,164.77
Administration expenses 21,699,810.10 17,951,497.63
Financial expenses 3,515,554.18 11,470,667.32
Losses of devaluation of asset -297,612.60 -102,025.86
Add: Changing income of fair
value(Loss is listed with ―-‖)
Investment income (Loss is listed
9,003,930.24 8,459,883.59
with ―-‖)
Including: Investment income on
9,003,930.24 8,459,883.59
affiliated company and joint venture
II. Operating profit (Loss is listed
-2,787,393.75 -5,683,469.05
with ―-‖)
Add: Non-operating income 505,506.53 3,054,118.66
Less: Non-operating expense 8.38 3.97
Including: Disposal loss of
non-current asset
III. Total Profit (Loss is listed with -2,281,895.60 -2,629,354.36
12
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
―-‖)
Less: Income tax expense 2,129,973.08
IV. Net profit (Net loss is listed with
-2,281,895.60 -4,759,327.44
―-‖)
V. Earnings per share -- --
i. Basic earnings per share
ii. Diluted earnings per share
VI. Other consolidated income
VII. Total comprehensive income -2,281,895.60 -4,759,327.44
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
5. Consolidated profit statement (year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Item Amount in this period Amount in last period
I. Total operating income 13,496,523,170.35 11,138,858,243.01
Including: Operating income 13,496,523,170.35 11,138,858,243.01
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 13,055,103,583.27 10,855,224,035.32
Including: Operating cost 12,255,445,722.21 10,141,428,776.70
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 36,252,178.16 25,667,811.97
Sales expenses 344,388,124.93 331,243,281.36
Administration expenses 279,078,781.03 254,207,873.90
Financial expenses 123,265,888.67 95,860,708.66
Losses of devaluation of asset 16,672,888.27 6,815,582.73
Add: Changing income of fair
value(Loss is listed with ―-‖)
Investment income (Loss is listed
25,020,090.00 21,270,172.89
with ―-‖)
Including: Investment income on 25,020,090.00 21,270,172.89
13
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
affiliated company and joint venture
Exchange income (Loss is listed
with ―-‖)
III. Operating profit (Loss is listed
466,439,677.08 304,904,380.58
with ―-‖)
Add: Non-operating income 27,072,897.87 19,497,223.63
Less: Non-operating expense 30,500,555.57 294,922.39
Including: Disposal loss of
9,027,535.66 109,996.54
non-current asset
IV. Total Profit (Loss is listed with
463,012,019.38 324,106,681.82
―-‖)
Less: Income tax expense 98,516,506.38 75,923,291.53
V. Net profit (Net loss is listed with
364,495,513.00 248,183,390.29
―-‖)
Including: net profit realized
before consolidation by mergered -240,695.14 -478,833.47
party
Net profit attributable to owner’s of
357,075,630.31 245,760,636.92
parent company
Minority shareholders’ gains and
7,419,882.69 2,422,753.37
losses
VI. Earnings per share -- --
i. Basic earnings per share 1.239 0.853
ii. Diluted earnings per share 1.239 0.853
VII. Other consolidated income
VIII. Total comprehensive income 364,495,513.00 248,183,390.29
Total consolidated income
attributable to owners of parent 357,075,630.31 245,760,636.92
company
Total consolidated income
7,419,882.69 2,422,753.37
attributable to minority shareholders
The merger realized net profit RMB -240,695.14 before consolidation during enterprises consolidation under a
same control.
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
6. Profit Statement of parent company (year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Items Amount in this period Amount in last period
I. Operating income 1,611,320,742.34 1,466,936,940.92
Less: operating cost 1,533,819,509.57 1,394,818,434.22
Operating tax and extras 4,015,503.39 3,079,873.50
Sales expenses 34,323,702.94 35,131,140.36
Administration expenses 40,489,753.67 37,283,777.36
14
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Financial expenses 15,666,378.68 28,289,487.66
Losses of devaluation of asset -385,458.17 150,888.54
Add: Changing income of fair
value(Loss is listed with ―-‖)
Investment income (Loss is listed
342,092,885.99 256,330,651.56
with ―-‖)
Including: Investment income on
25,020,090.00 21,270,172.89
affiliated company and joint venture
II. Operating profit (Loss is listed
325,484,238.25 224,513,990.84
with ―-‖)
Add: Non-operating income 822,021.74 5,636,496.77
Less: Non-operating expense 270,566.98 3.97
Including: Disposal loss of
69,125.07 0.00
non-current asset
III. Total Profit (Loss is listed with
326,035,693.01 230,150,483.64
―-‖)
Less: Income tax expense 2,298,245.25 5,360,505.58
IV. Net profit (Net loss is listed with
323,737,447.76 224,789,978.06
―-‖)
V. Earnings per share -- --
i. Basic earnings per share
ii. Diluted earnings per share
VI. Other consolidated income
VII. Total comprehensive income 323,737,447.76 224,789,978.06
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
7. Consolidated Cash Flow Statement (year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Item Amount in this period Amount in last period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 12,752,376,314.27 10,532,981,669.68
services
Net increase of customer deposit and
interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
investment
Net increase of disposal of
transaction financial asset
Cash received from interest,
commission charge and commission
15
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 1,645,597.88 1,037,653.73
Other cash received concerning
82,642,098.78 91,301,719.02
operating activities
Subtotal of cash inflow arising from
12,836,664,010.93 10,625,321,042.43
operating activities
Cash paid for purchasing
commodities and receiving labor 11,861,241,353.99 9,973,672,262.44
service
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 358,441,169.10 322,989,852.09
Taxes paid 371,596,474.36 266,122,534.50
Other cash paid concerning
233,299,748.68 251,879,449.87
operating activities
Subtotal of cash outflow arising
12,824,578,746.13 10,814,664,098.90
from operating activities
Net cash flows arising from
12,085,264.80 -189,343,056.47
operating activities
II. Cash flows arising from investing
activities:
Cash received from recovering
1,833,000.00
investment
Cash received from investment
13,520,461.47 17,595,000.00
income
Net cash received from disposal of
fixed, intangible and other long-term 54,082,155.99 4,063,113.42
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
650,072.37
investing activities
Subtotal of cash inflow from
67,602,617.46 24,141,185.79
investing activities
Cash paid for purchasing fixed,
146,451,305.64 139,579,470.77
intangible and other long-term assets
Cash paid for investment
Net increase of mortgaged loans
Net cash received from subsidiaries
55,451,762.22 5,721,335.24
and other units
Other cash paid concerning investing
9,784,633.68
activities
Subtotal of cash outflow from
201,903,067.86 155,085,439.69
investing activities
16
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Net cash flows arising from
-134,300,450.40 -130,944,253.90
investing activities
III. Cash flows arising from
financing activities
Cash received from absorbing
investment
Including: Cash received from
absorbing minority shareholders’
investment by subsidiaries
Cash received from loans 840,603,970.24 704,180,383.69
Cash received from issuing bonds 398,400,000.00
Other cash received concerning
252,631,051.81 643,907,133.91
financing activities
Subtotal of cash inflow from
1,491,635,022.05 1,348,087,517.60
financing activities
Cash paid for settling debts 918,491,964.16 458,490,493.30
Cash paid for dividend and profit
153,290,704.45 99,470,808.16
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by 915,144.07 1,489,758.64
subsidiaries
Other cash paid concerning
570,193,419.23 588,086,151.27
financing activities
Subtotal of cash outflow from
1,641,976,087.84 1,146,047,452.73
financing activities
Net cash flows arising from
-150,341,065.79 202,040,064.87
financing activities
IV. Influence on cash and cash
equivalents due to fluctuation in 8,041.67 -13,288.37
exchange rate
V. Net increase of cash and cash
-272,548,209.72 -118,260,533.87
equivalents
Add: Balance of cash and cash
907,884,162.14 684,764,869.84
equivalents at the period -begin
VI. Balance of cash and cash
635,335,952.42 566,504,335.97
equivalents at the period -end
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
8. Cash Flow Statement of parent company (year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
Unit: CNY
Item Amount in this period Amount in last period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 1,662,451,442.57 1,582,721,158.31
services
Write-back of tax received
Other cash received concerning
16,338,339.91 13,528,398.19
operating activities
Subtotal of cash inflow arising from
1,678,789,782.48 1,596,249,556.50
operating activities
17
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Cash paid for purchasing
commodities and receiving labor 1,633,946,690.73 1,590,198,109.09
service
Cash paid to/for staff and workers 33,994,046.58 31,799,371.78
Taxes paid 20,053,311.69 17,415,084.04
Other cash paid concerning
22,068,405.14 37,825,100.83
operating activities
Subtotal of cash outflow arising
1,710,062,454.14 1,677,237,665.74
from operating activities
Net cash flows arising from
-31,272,671.66 -80,988,109.24
operating activities
II. Cash flows arising from investing
activities:
Cash received from recovering
1,830,000.00
investment
Cash received from investment
123,264,318.99 96,016,500.73
income
Net cash received from disposal of
fixed, intangible and other long-term 207,900.00 3,239,648.92
assets
Net cash received from disposal of
5,424,600.00
subsidiaries and other units
Other cash received concerning
295,783,271.97 251,989,281.47
investing activities
Subtotal of cash inflow from
424,680,090.96 353,075,431.12
investing activities
Cash paid for purchasing fixed,
1,799,057.00 3,360,428.22
intangible and other long-term assets
Cash paid for investment 10,000,000.00 55,321,335.24
Net cash received from subsidiaries
85,598,000.00
and other units
Other cash paid concerning investing
594,080,000.00 213,544,100.00
activities
Subtotal of cash outflow from
691,477,057.00 272,225,863.46
investing activities
Net cash flows arising from
-266,796,966.04 80,849,567.66
investing activities
III. Cash flows arising from
financing activities
Cash received from absorbing
investment
Cash received from loans 160,000,000.00 270,000,000.00
Cash received from issuing bonds 398,400,000.00
Other cash received concerning
648,349,929.11 949,038,879.26
financing activities
Subtotal of cash inflow from
1,206,749,929.11 1,219,038,879.26
financing activities
Cash paid for settling debts 130,164,459.99 210,000,000.00
Cash paid for dividend and profit
81,187,208.13 81,268,773.85
distributing or interest paying
Other cash paid concerning
800,026,956.78 905,462,372.49
financing activities
Subtotal of cash outflow from
1,011,378,624.90 1,196,731,146.34
financing activities
18
China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2012 (Full-Text)
Net cash flows arising from
195,371,304.21 22,307,732.92
financing activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
-102,698,333.49 22,169,191.34
equivalents
Add: Balance of cash and cash
164,840,499.86 135,498,819.87
equivalents at the period -begin
VI. Balance of cash and cash
62,142,166.37 157,668,011.21
equivalents at the period -end
Legal representative: Wei Yulin
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Chi Guoguang
(II) Auditing Report
Auditing Opinion: Unaudited
China National Accord Medicines Corporation Ltd.
Chairman: Wei Yulin
24 October 2012
19
